SecBot SecBot
6-K ·Filed Mar 31, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago SEC0001213900-26-036954
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should monitor the full data presentation at DDW on May 2 for insights into efficacy and safety, which could catalyze near-term upside. Positive results may attract institutional interest or collaboration offers, particularly given the unmet need in pancreatic cancer.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · Mar 31, 2026 · via day close
Latest settled
+105.88%
T+60 · $2.10
Vs SPY
+93.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $1.02entry
  2. T+1 · 8mo ago 0.00%α −0.75% · $1.02
  3. T+5 · 7mo ago 0.00%α −3.94% · $1.02
  4. T+20 · 7mo ago −14.58%α −24.00% · $0.8713
  5. T+60 · 5mo ago +105.88%α +93.50% · $2.10

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced that clinical data from its Alpha DaRT therapy for pancreatic cancer has been accepted for an oral presentation at Digestive Disease Week (DDW) 2026, marking the first time this data will be presented at a major gastroenterology conference. This represents a significant milestone in validating the scientific and clinical potential of its technology for a high-need indication.

Key Facts

  • Alpha DaRT pancreatic cancer clinical data accepted for oral presentation at DDW 2026, the premier gastroenterology conference.
  • Presentation based on combined results from two first-in-human trials at Hadassah Medical Center in Jerusalem.
  • Data to be presented on May 2, 2026, by Dr. Harold Jacob, Principal Investigator.
  • Company highlights this as a key milestone supporting ongoing clinical development, including the U.S.-based IMPACT pilot study.
  • Pancreatic cancer is a high-mortality disease with limited treatment options, especially for inoperable cases.

Financial Impact

No direct financial impact disclosed; potential for increased investor and clinical interest leading to future funding or partnership opportunities.

market sentimentR&D valuationpartnership potential

Risk Factors

  • Data presented may be preliminary or limited in sample size.
  • Forward-looking statements emphasize risks including regulatory approval, funding needs, and clinical trial enrollment.
  • No guarantee that presentation will lead to commercial or regulatory advancement.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-036954
Document: ea028432201ex99-1.htm0001213900-26-036954
Document: 0001213900-26-036954-index-headers.html0001213900-26-036954
Document: 0001213900-26-036954-index.html0001213900-26-036954
Document: 0001213900-26-036954.txt0001213900-26-036954

US Market Status

Market Closed · Opens in 7h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026